IONS Q3 2018 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$12B

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$145M+22.9% YoY

Gross Profit

$145M100.0% margin

Operating Income

-$19M-12.8% margin

Net Income

-$5M-3.1% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+23.5%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$31M

Stock-Based Comp.

$35M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.4B

Stockholders' Equity

$711M

Cash & Equivalents

$480M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$118M	+22.9%
Gross Profit	$145M	$38M	+281.6%
Operating Income	-$19M	$11M	-264.2%
Net Income	-$5M	-$3M	-74.6%

Revenue Segments

Commercial

$83M36%

SPINRAZA Royalties

$70M31%

Research and Development Revenue Under Collaborative Agreements

$63M27%

Licensing and Other Royalties

$13M6%